MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from offering,
net of commissions
$108,154K
Proceeds from exercises
of warrants
$10,757K
Proceeds from exercises
of stock options
$2,079K
Proceeds from
disgorgement of beneficial...
$725K
Proceeds from employee
stock purchase plan
$118K
Net cash provided by
financing activities
$121,013K
Canceled cashflow
$820K
Net (decrease)
increase in cash and cash...
-$15,183K
Canceled cashflow
$121,013K
Proceeds from maturities
of...
$76,567K
Stock-based compensation
$5,185K
Operating lease
right-of-use assets
$437K
Depreciation and
amortization
$144K
Write off of deferred
offering costs
$26K
Loss on disposal of
property, equipment and...
-$7K
Payments of offering
costs
$809K
Payments of finance lease
$11K
Net cash used in
investing activities
-$94,107K
Canceled cashflow
$76,567K
Net cash used in
operating activities
-$42,089K
Canceled cashflow
$5,799K
Interest income, net
$6,536K
Purchases of
available-for-sale marketable...
$170,662K
Purchases of property,
equipment and leasehold...
$12K
Net loss
-$42,759K
Canceled cashflow
$6,536K
Accretion of
available-for-sale marketable...
$1,638K
Prepaid expenses and
other current assets
$1,478K
Accrued expenses and
other liabilities
-$1,415K
Accounts payable
-$598K
Employee compensation
(excluding stock...
$11,820K
Other segment items
$8,853K
Chronic cough in ipf
clinical trial expense
$7,992K
Other clinical trials
and studies
$6,219K
Other clinical
development expenses
$5,942K
Stock compensation
expense
$5,185K
Clinical trial material
$1,827K
Refractory chronic cough
clinical trial expense
$1,457K
Back
Back
Cash Flow
source: myfinsight.com
Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI)